medRxiv preprint doi: https://doi.org/10.1101/2023.12.04.23299403; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

# <sup>1</sup> Understanding the key determinants of an HPV <sup>2</sup> therapeutic vaccine: a modeling analysis

3

4 Jamie A. Cohen<sup>1\*</sup>, Robyn M. Stuart<sup>2^</sup>, Serin Lee<sup>1^,3</sup>, Daniel J. Klein<sup>1</sup>, Cliff C. Kerr<sup>1</sup>, Darcy W. 5 Rao<sup>2</sup>, Haina Shin<sup>4</sup>, Sharon L. Achilles<sup>4</sup> 6 7 <sup>1</sup> Institute for Disease Modeling, Global Health Division, Bill & Melinda Gates Foundation, Seattle, Washington, 8 USA 9 <sup>2</sup> Data & Insights, Gender Equality Division, Bill & Melinda Gates Foundation, Seattle, Washington, USA 10 <sup>3</sup> Department of Industrial & Systems Engineering, University of Washington, Seattle, Washington, USA 11 <sup>4</sup> Reproductive Health Technologies, Global Health Division, Bill & Melinda Gates Foundation, Seattle, 12 Washington, USA 13 14 ^ Contractor on assignment 15 \* Corresponding author: jamie.cohen@gatesfoundation.org 16

# 17 Abstract

18 Despite incredibly effective tools to prevent HPV infection and treat precancerous lesions, 19 the scale-up of existing interventions in most low and middle-income countries has been 20 slow, leaving a residual burden of invasive cervical cancer that will persist for decades. An 21 HPV therapeutic vaccine may overcome some of the scalability and infrastructure challenges 22 of traditional screening and treatment programs, though its potential public health value 23 depends upon its characteristics, delivery strategy, and the underlying immunity of the 24 population on which it would act. This analysis uses HPVsim, an open-access agent-based 25 simulation framework, to evaluate the impact of a range of potential HPV therapeutic 26 vaccines with varying scale-up of existing preventive interventions in nine high-burden low-27 and middle-income countries (LMICs). For each setting, the model is populated with context-specific demographic and behavioral data, and calibrated to fit estimates of HPV 28 29 and cervical disease by age. We find that an HPV therapeutic vaccine that clears 90% of 30 virus and regresses 50% of high-grade lesions, reaching 70 percent of 35-45 year old 31 women starting in 2030, could avert 1.2-2.2 million incident cases of cervical cancer, 32 500,000-1.2 million cervical cancer deaths and 20-40 million disability adjusted life years 33 (DALYs) in the modeled high-burden LMICs over 30 years. The size of the impact is 34 sensitive to rates of background intervention scale-up and the characteristics of the vaccine, 35 including ability to establish long-lasting immune memory.

#### 1. Introduction 37

38 Cervical cancer elimination, defined as reaching and maintaining an incidence rate of below 39 4 per 100,000 women, is an important global public health goal, with the potential to avert 40 over 300,000 deaths globally per year. Modeling has estimated that cervical cancer 41 elimination can be achieved through rapid adoption and scale-up of prophylactic 42 vaccination to 90% of young girls, screening 70% of women between ages 30 and 50 years 43 for pre-cancer, and treatment of 90% of detected pre-cancers and cancers. However, most 44 low and lower-middle income countries (LMICs) remain far from reaching these 90-70-90 45 WHO elimination targets (1-3). As of 2019, only 40% of LMICs had introduced HPV 46 vaccination into their national programs and only 15% of girls in the target age for HPV 47 vaccination had received two doses (4). Only 10% of eligible women have ever received 48 screening in LMICs, compared to 84% of women in high-income countries (5). 49 50

HPV prophylactic vaccines have the potential to significantly reduce the burden of cervical

51 cancer by preventing the acquisition of high-risk HPV. The main targeted population for 52

HPV prophylactic vaccines is girls aged 9-14 years. Despite the significant promise of this 53 intervention, scale-up has been challenged by vaccine hesitancy, insufficient supply, and a

54 scarcity of delivery platforms for this specific age group, which is not otherwise traditionally

55 reached by vaccination programs. Additionally, even with optimistic scale-up of

56 prophylactic vaccination, reductions in cervical cancer burden will not accrue until several

57 decades into the future, and will not be realized by women who missed prophylactic

58 vaccination prior to HPV infection and remain at risk of persistent oncogenic infection that

- 59 can progress to cervical cancer.
- 60

61 For unvaccinated women, screening is the most effective tool for early identification of pre-62 cancerous lesions with subsequent treatment that prevents progression (6, 7). HPV DNA 63 testing has transformed the ability to detect high-risk infection with a high degree of 64 sensitivity, and thermal ablation has enabled low-cost treatment of precancerous lesions (8-65 12). Screening and treatment programs remain expensive and challenging to scale-up in 66 many LMIC geographies (13–15). The high cost of HPV DNA tests often leads to reliance on 67 visual inspection with acetic acid (VIA), which is known to have both low sensitivity and 68 variable performance, resulting in imprecise treatment decisions. Further, since screening

- 70 (16-18).
- 71

69

72 Several therapeutic vaccines have been tested, with varying success. Vaccines targeting

and treatment are not typically done in a single visit, there is significant loss to follow-up

73 early stage invasive cervical cancer and high-grade lesions have been tested in clinical trials,

74 several products that work to clear infection have reached phase 1/2a trials, and one

75 candidate targeting productive infection is in early stages of discovery (19-21). These HPV

- 76 therapeutic vaccines have the potential to meet the needs of women who have been
- 77 missed by prophylactic vaccination and may circumvent some of the scalability and
- 78 infrastructure challenges of traditional screening and treatment programs. However, the
- 79 impact of a therapeutic vaccine depends upon how quickly it can be developed and
- 80 delivered, the characteristics of the product and its mechanism of action, and the degree
- 81 and timing of scale-up of prophylactic vaccination and screening and treatment.
- 82
- 83 Resources devoted to discovery and development of such a product have a high
- 84 opportunity cost, as they could alternatively support the scale-up of existing interventions.
- 85 Therefore, understanding the full public health value of an HPV therapeutic vaccine under a
- 86 range of plausible future scenarios and against scientific uncertainty is critical. To date,
- 87 there has been one published study (22) that uses dynamic modeling to evaluate the
- 88 potential impact of an HPV therapeutic vaccine in Uganda. The present study builds from
- 89 that analysis by exploring the impact of potential HPV therapeutic vaccine candidates with
- 90 varying efficacy for virologic clearance and regression of high-grade pre-cancer, as well as
- 91 its ability to induce long-term memory. We quantify the incremental impact of potential
- 92 HPV TxV candidates in nine high-burden low and middle-income countries with a large
- 93 burden of disease and low coverage of screening and treatment.
- 94

# 95 2. Methods

### 96 2.1 Methods overview

- 97 Using HPVsim, an open-access agent-based simulation framework for estimating the98 burden of cervical cancer, we calibrated nine models to epidemiologic data in India,
- 99 Indonesia, Bangladesh, Myanmar, Ethiopia, Nigeria, Democratic Republic of Congo,
- 100 Uganda, and Tanzania. These countries were chosen based upon their cumulative disease
- 101 burden and current membership in GAVI. The HPVsim platform is described in Stuart et al.
- 102 (23) and in the supplemental appendix. Briefly, HPVsim simulates individual agents who age
- 103 over time, participate in structured sexual networks, and can acquire genotype-specific HPV
- 104 infection. HPV can clear and lead to seroconversion and associated B- and T-cell immunity
- 105 which protects against subsequent type-specific HPV acquisition and progression, or
- 106 persist. Persistent high-risk infections have an accumulating risk of progression to invasive
- 107 cervical cancer over time in the absence of an intervention.
- 108
- 109 In the remainder of this section, we provide details on how the models were calibrated
- 110 (Section 2.1) and the scenarios and sensitivity analyses that we ran (Section 2.2). All analysis
- 111 code is publicly available <u>online</u>, as is the <u>HPVsim</u> model itself.
- 112

## 113 2.1. Model calibration and validation

- 114 We calibrated nine models by adjusting a subset of the model's input parameters in order
- 115 to achieve a good match to estimates on cervical cancer cases by age and, where data was
- available, the distribution of HPV types among women with precancerous lesions and
- 117 invasive cervical cancer. In all countries, we prophylactic vaccination and screening and
- 118 treatment are low or absent; we make a simplifying assumption of no prophylactic
- 119 vaccination or screening and treatment programs prior to 2020. Details and results of the
- 120 calibration procedure can be found in section 1.3 of the supplemental appendix.
- 121

## 122 2.2. Scenario analyses

- 123 The impact of a therapeutic vaccine is highly dependent on the relative scaleup of
- 124 screening for pre-cancer and treatment of pre-cancer and invasive cervical cancer. We
- 125 assume that scale-up of TxV is unlikely in the absence of PxV, such that all modeled
- 126 scenarios include 90% coverage of PxV. Scale-up of routine screening and treatment (S&T),
- 127 however, has been more challenging and may continue to be delayed or absent, and we
- 128 evaluate a range of scenarios of S&T scale-up (Table 1). For each scenario, we first estimate
- 129 residual burden until 2060 in the absence of therapeutic vaccination to formulate a baseline
- 130 counterfactual against which to evaluate a therapeutic vaccine. We then run the scenarios
- 131 with TxV and compute the number of cervical cancer cases, deaths, and DALYs averted
- 132 from 2030 to 2060.
- 133

	Prophylactic vaccination	Screening & treatment (S&T)
Scenario 1	90% coverage	0% screen and treatment coverage
Scenario 2	90% coverage	35% screen coverage, 70% treatment coverage
Scenario 3	90% coverage	70% coverage, 90% treatment coverage

- **Table 1.** Prophylactic vaccine and S&T scenarios considered. Lifetime coverage of S&T has
- been estimated at less than 5% in all settings, though there might be significant regionalvariation.
- 137
- 138 We assume the nonavalent HPV prophylactic vaccination is introduced in each country in
- 139 2025 and administered to 9-14 year old girls, reaching 90 percent coverage level
- 140 immediately. Vaccination is assumed to generate high and long-lasting type-specific
- 141 immunity against infection. The level of protection is drawn per person at the time of
- 142 vaccination and applied per sex act, meaning the vaccine is modeled as a "leaky vaccine"
- 143 (24). Screening is similarly introduced in 2025 and consists of an HPV DNA test for women

- 144 twice in their lifetime between ages 30 and 50, reaching the target coverage level
- 145 immediately. Women who receive a positive result are eligible for ablative or excisional
- 146 treatment, with 81 and 93 percent efficacy in regressing pre-cancerous lesions respectively.
- 147
- 148 On top of these alternative prophylactic vaccination and S&T scenario, we evaluate a range
- 149 of scenarios varying the characteristics and delivery of an HPV therapeutic vaccine (see
- 150 Table 2). We consider targeting 30, 35, or 40-year-old women for routine delivery starting in
- 151 2030, and conduct a one-time campaign in 2030 reaching women between the target age
- and the next 10 birth cohorts. For all scenarios, we assume the product would require two
- doses administered 3 months apart, and that 70% of eligible women are reached with the
- 154 first dose and that 20% of women who receive their first dose will not return for their second
- dose. We assume the first dose will provide half the efficacy of the completed regimen.
- 156

	Base case	Sensitivity
TxV effectiveness	90/0, 70/30, 50/50, 90/50	N/A
Target age of routine administration	30, 35, 40	N/A
Age of catch-up campaign (in 1 <sup>st</sup> year of introduction)	Target age – target age + 10	N/A
TxV immune memory	Maximum of efficacy against virus and lesion Waning: lifelong	No durable memory
Coverage	70% first-dose coverage, 20% LTFU between doses	N/A
Doses	2-doses, 3 months apart	N/A
Introduction year	2030	2035
Cross-protection	None	50% cross protection against all other high-risk genotypes

157 Table 2. Therapeutic vaccine assumptions in base case and values considered in sensitivity

analyses. Effectiveness values (e.g., 90/0) represent full effectiveness of a completed 2-

dose regimen in clearing HPV infection as the first value (i.e., 90%) and regressing pre-

160 cancer as the second (i.e., 0%). TxV: HPV therapeutic vaccine.

- 162 In the absence of trial data on effectiveness of a therapeutic vaccine product, we conducted
- 163 robust exploration around therapeutic vaccine properties, varying effectiveness against
- 164 productive infections from 50 to 100% and against high-grade lesions from 0 to 50%. An
- 165 upper-bound of 50% effectiveness at regressing high-grade lesions was imposed based
- 166 upon modest results of previous therapeutic vaccines that have targeted high-grade lesions
- and cervical cancer and the expectation that the microenvironment would be less
- 168 conducive for stimulating a response that would effectively regress high-grade lesions (25).
- 169
- 170 The relative impact of the therapeutic vaccine depends on how effective it is at both
- 171 virological clearance and lesion regression. It is expected that this vaccine will work by
- 172 inducing a CD8 T-cell response that will clear active infection and/or lesion (26). The
- 173 magnitude, breadth, and duration of that immune response will depend upon the
- 174 immunogen design of the vaccine, existing HPV-specific T-cell repertoire, and mode of
- 175 delivery.
- 176
- 177 In the base case, we assume the therapeutic vaccine will provide no cross protection
- against other high risk HPV types. We assume that the therapeutic vaccine acts on prevalent
- 179 infection and/or lesion, based upon its attributes, and induces the same level of long-lasting
- 180 immunity to reduce the severity of future infections and reactivations as the effectiveness
- 181 generated by each dose of the therapeutic vaccine.
- 182

183 The relative impact of the therapeutic vaccine depends on how effective it is at both

- 184 virological clearance and lesion regression. It is expected that this vaccine will work by
- 185 inducing a CD8 T-cell response that will clear active infection and/or lesion (26). The
- 186 magnitude, breadth, and duration of that immune response will depend upon the
- 187 immunogen design of the vaccine, existing HPV-specific T-cell repertoire, and mode of
- 188 delivery. Given this uncertainty, we consider the impact of immune memory and
- 189 effectiveness of such a product on its potential public health impact, co-varying the level of
- 190 immunity against disease from a future infection and the vaccine's effectiveness against
- 191 prevalent virus and lesion.
- 192
- 193We run each scenario multiple times using the best fitting parameter set and 5 different194random seeds and present the mean and  $\pm$  two times standard deviation of the results.
- 195
- 196 3. Results
- 197 3.1 Residual burden

198 We find a large residual burden of cervical cancer over the next 35 years for all scale-up

199 scenarios without TxV for all countries modeled, with the majority of burden driven by India.

- 200 Even in the context of optimistic prophylactic vaccination and S&T scale-up (achieving the
- 201 90-70-90 WHO elimination targets) in all 9 countries, the model estimates over 200,000
- new cases of cervical cancer each year (see Figure 1). 202



203

204 Figure 1. Residual annual burden of incident cervical cancers in nine high-burden LMICs 205 from 2020 until 2060, assuming different rates of S&T coverage scale-up. S&T: screening 206 and treatment. Top panel plots the cumulative residual burden across all nine countries. 207

#### 3.2 Therapeutic vaccine impact 208

- 209 We first consider the relationship between age of targeted routine TxV delivery, TxV
- 210 characteristics, and background scale-up of PxV and S&T. The impact of TxV on cervical
- 211 cancer cases, deaths, and DALYs is greatest for a product that clears virus with 90%
- 212 effectiveness and regresses CIN2+ with 50% effectiveness (Figure 2). With background
- 213 screening and treatment coverage and ages held fixed, TxV effectiveness against pre-
- 214 cancerous lesion yields the biggest impact over the short term, while TxV with effectiveness
- 215 in clearing virus has delayed impact.
- 216
- 217 For all three metrics, the health impact is greatest for a TxV candidate that clears virus with 218 90% effectiveness and regresses pre-cancerous lesion with 50% effectiveness and in the
- 219 absence of screening and treatment scale-up. The time series plot in Figure 2 shows the
- 220 timescales of impact holding fixed the level of background screening and treatment
- 221 coverage and age of administration, whereby effectiveness against pre-cancerous lesion
- 222 yields the biggest impact over the short term, while effectiveness against virus has a
- 223 delayed impact. TxV candidates with 50% effectiveness against precancerous lesions have
- 224 the highest early impact, but at 7 years post-introduction the impact of the product that
- 225 also has 50% effectiveness for viral clearance (orange line in Figure 2) begins to level off
- 226 compared to the candidate with 90% effectiveness for viral clearance (blue line). The impact
- 227 of a candidate with 90% viral clearance and no impact on precancerous lesions (yellow line)
- 228 converges with candidates with moderate impact on precancerous lesions and lower viral
- 229 clearance (orange and purple lines) approximately 25 years post-introduction.
- 230
- 231 When we consider the trade-off between effectiveness against virus and high-grade pre-232 cancer alongside age of administration, we find the age target that maximizes cancer cases
- 233 and deaths averted switches from 30 to 35 to 40 as lesion regression effectiveness grows
- 234 from 0 to 30 to 50%. Irrespective of screening and treatment scale-up, there is more value
- 235 to regressing high grade lesions for older women than younger women. This can be
- 236 visualized by the slope of the green lines in Figure 2, representing administration to women
- 237 age 40, always being steeper than the tan (age 35) and red (age 30) lines. The slope of all
- 238 three lines flattens as screening and treatment coverage increases from 0 to 35 to 70%,
- 239 indicating that there is a smaller difference in age of administration for different candidates. 240
- 241 When using DALYs as a metric of health impact, targeting women age 30 remains the most
- 242 effective until the effectiveness against high-grade lesions reaches 50%. For all other TxV
- 243 candidates and levels of screening and treatment scale-up, targeting age 35 maximizes
- 244 DALYs averted.
- 245





247 Figure 2. Health impact of an HPV therapeutic vaccine summed across nine high-burden LMICs based upon effectiveness, background intervention scale-up, and age of 248 249 administration. Effectiveness values (i.e. 90/0) represent full effectiveness of a completed 2-250 dose HPV therapeutic vaccine regimen in clearing HPV infection first (i.e. 90%) and 251 regressing high grade pre-cancer second (i.e. 0%). Time series plotted for the background

252 intervention scenario of 90% PxV coverage and no S&T scale-up only and for a target TxV

- 253 age of 35.
- 254
- 255 We then explored the extent to which these findings are consistent across settings,
- 256 hypothesizing that the biggest differences would be seen in settings with different
- 257 epidemiologic age profiles. To do this, we compared the health impact of TxV in Nigeria,
- 258 with a median age of cancer of 45, to India, with a median age of cancer of 55,
- 259 representative of both extreme ends of the spectrum within our nine modeled countries.

- 260 The age that maximizes DALYs averted is equivalent or younger in Nigeria than in India for
- 261 every candidate profile and background level of screening and treatment coverage. In
- 262 Nigeria, it is always optimal to target 30 year-old women for routine administration of TxV,
- 263 whereas the optimal age in India depends upon the TxV effectiveness against virus and
- 264 lesion as well as background level of screening and treatment coverage. In both settings,
- 265 the overall health impact increases monotonically with more effectiveness against pre-
- 266 cancerous lesion for each age target.
- 267





269 Figure 3. First row shows the distribution of age of causal HPV infection, CIN2+, and cancer 270 in Nigeria and India. The second row shows DALYs averted due to administration of an HPV 271 therapeutic vaccine in Nigeria and India based upon effectiveness, background intervention 272 scale-up, and age of administration.

- 274 To understand the additional important levers that might influence the value of a TxV, we
- considered the inclusion of 50% cross-protection against other high-risk genotypes, a 5-
- 276 year delay in the introduction of such a TxV candidate, and the absence of durable immune
- 277 protection. We considered these three sensitivity analyses for a TxV candidate with the
- 278 most optimistic effectiveness profile, with delivery targeting 30, 35, or 40 year old women.
- 279 Figure 4 shows the associated impact on DALYs averted compared to baseline for each
- sensitivity analyses, both cumulatively and individually per country.
- 281
- Adding in 50% cross-protection would avert an additional 5-7 million DALYs over 30 years
- compared to the same TxV candidate with no cross protection, with significant variation
- across countries. Cross protection would increase DALYs averted by up to 28% in Nigeria,
- where nearly 40 percent of cervical cancers are attributable to non-16/18 HPV types,
- whereas it would have a negligible impact on DALYs averted in DRC, where less than 5% of
- 287 cervical cancers are attributable to non-16/18 HPV types. In contrast, delaying TxV
- introduction by 5 years would result in over 10 million fewer DALYs averted, with
- significantly less variation by country.
- 290
- 291 Most notable is the loss in health impact associated with a TxV candidate without durable
- immune memory, with both tremendous variation by age of delivery and by country. For all
- 293 countries, there is a larger loss in DALYs averted when TxV is administered to 30 year-olds
- than 35 or 40 year-olds, reflecting the fact that women at younger ages might not yet have
- 295 acquired the infection/lesion that would progress to invasive cervical cancer in the absence
- 296 of treatment. More striking is the difference across countries, with the lack of durable
- immune memory having the smallest impact on DALYs averted in Nigeria (0-25% fewer than
- 298 with immune memory) and the largest impact in Tanzania (50-75% fewer). These differences
- 299 reflect associated differences in the age distribution of infection and cancer, with Nigeria
- 300 having a nearly 15-year younger age of causal HPV infection than Tanzania.



301 302 Figure 4. Sensitivity analysis of cross-protection for non-16/18 high-risk genotypes, delaying 303 TxV introduction by 5 years, and absence of durable immune memory. All findings 304 presented assume no screening and treatment. 305

#### 4. Discussion 306

307 Using a robust dynamic simulation model fit to 9 high-burden LMICs, we find that HPV TxV 308 can have a significant impact on burden of disease, and that this impact depends strongly 309 on scale-up of screening and treatment and TxV candidate characteristics. Importantly, we 310 find that a TxV that has some effectiveness at regression of high-grade lesions accelerates 311 and increases burden reduction relative to one that only clears productive infection. This 312 mirrors the delayed impact of prophylactic vaccines due to the age of administration and 313 mechanism of impact and reveals the cost of a therapeutic vaccine without significant action 314 against pre-cancerous lesions - it leaves avertable DALYs on the table. Putting these results

- in context, we find that, even with the WHO 90-70-90 targets for PxV and S&T and in a
- 316 short-term time horizon evaluation, an HPV therapeutic vaccine could avert over 20 million
- 317 DALYs in nine high-burden LMICs over 30 years. Given that product development will take
- 318 place in parallel with ongoing efforts to scale up existing cervical cancer programming, this
- 319 analysis reveals that a therapeutic vaccine would likely have tremendous benefit regardless
- of the level of progress made with these parallel efforts.
- 321
- 322 This study finds that an HPV therapeutic vaccine might avert 1-2 million incident cases of
- 323 cervical cancer, 400,000 1.2 million deaths from cervical cancer, and 20-40 million DALYs
- in nine high-burden LMICs over 30 years, depending upon the TxV candidate characteristics
- 325 and level of intervention scale-up. The findings in this analysis are aligned with the results of
- the Spencer et al. analysis (22), which found 139,000 fewer incident cervical cancers
- 327 associated with an HPV therapeutic vaccine delivered to women in Uganda (compared to
- 328 approximately 120,000 incident cases averted in Uganda in the current analysis, see Figure
- A16 for details).
- 330
- 331 In addition to uncertainty in the scale-up of existing interventions and characteristics of a
- 332 potential TxV candidate, there also exists real uncertainty and variation in many of the
- 333 mechanisms and processes being modeled, including in behavior and natural history. This
- variation might reveal contexts in which an HPV therapeutic vaccine would have more
- impact relative to other contexts or might target different age groups to maximize value,
- due to factors such as different patterns of sexual behavior. Our analysis attempted to draw
- 337 out some of this variation by comparing across nine high-burden LMICs with significant
- 338 differences in epidemiologic profiles. Future work in this area should consider development
- 339 of sub-national models to capture real variation in epidemiology seen across and within
- settings (27) and should be applied to other settings with varied epidemiologic anddemographic patterns to test generalizability.
- 342

# 343 Acknowledgments

- We would like to thank Celina Schocken, Holger Kanzler, Ru Cheng, Sami Gottlieb, andHolly Prudden for their editorial and scientific review of this work.
- 346

# 347 References

- M. T. Hall, K. T. Simms, J.-B. Lew, M. A. Smith, J. M. Brotherton, M. Saville, I. H.
   Frazer, K. Canfell, The projected timeframe until cervical cancer elimination in
   Australia: a modelling study. *Lancet Public Health* 4, e19–e27 (2019).
- M.-C. Boily, R. V. Barnabas, M. M. Rönn, C. J. Bayer, C. van Schalkwyk, N. Soni, D. W.
   Rao, L. Staadegaard, G. Liu, R. Silhol, M. Brisson, L. F. Johnson, P. Bloem, S. Gottlieb,
   N. Broutet, S. Dalal, Estimating the effect of HIV on cervical cancer elimination in

medRxiv preprint doi: https://doi.org/10.1101/2023.12.04.23299403; this version posted December 4, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

354 South Africa: Comparative modelling of the impact of vaccination and screening. 355 eClinicalMedicine 54 (2022).

- 356 3. M. Brisson, J. J. Kim, K. Canfell, M. Drolet, G. Gingras, E. A. Burger, D. Martin, K. T. 357 Simms, É. Bénard, M.-C. Boily, S. Sy, C. Regan, A. Keane, M. Caruana, D. T. N. 358 Nguyen, M. A. Smith, J.-F. Laprise, M. Jit, M. Alary, F. Bray, E. Fidarova, F. Elsheikh, P. 359 J. N. Bloem, N. Broutet, R. Hutubessy, Impact of HPV vaccination and cervical 360 screening on cervical cancer elimination: a comparative modelling analysis in 78 low-361 income and lower-middle-income countries. The Lancet **395**, 575–590 (2020).
- 362 4. L. Bruni, A. Saura-Lázaro, A. Montoliu, M. Brotons, L. Alemany, M. S. Diallo, O. Z. 363 Afsar, D. S. LaMontagne, L. Mosina, M. Contreras, M. Velandia-González, R. Pastore, 364 M. Gacic-Dobo, P. Bloem, HPV vaccination introduction worldwide and WHO and 365 UNICEF estimates of national HPV immunization coverage 2010-2019. Prev. Med. 144, 366 106399 (2021).
- 367 L. Bruni, B. Serrano, E. Roura, L. Alemany, M. Cowan, R. Herrero, M. Poljak, R. Murillo, 5. 368 N. Broutet, L. M. Riley, S. de Sanjose, Cervical cancer screening programmes and agespecific coverage estimates for 202 countries and territories worldwide: a review and 369 370 synthetic analysis. Lancet Glob. Health 10, e1115-e1127 (2022).
- 371 R. Landy, F. Pesola, A. Castañón, P. Sasieni, Impact of cervical screening on cervical 6. 372 cancer mortality: estimation using stage-specific results from a nested case-control 373 study. Br. J. Cancer 115, 1140-1146 (2016).
- 374 7. L. Peirson, D. Fitzpatrick-Lewis, D. Ciliska, R. Warren, Screening for cervical cancer: a 375 systematic review and meta-analysis. Syst. Rev. 2, 35 (2013).
- 376 8. O. Andrés-Gamboa, L. Chicaíza, M. García-Molina, J. Díaz, M. González, R. Murillo, M. 377 Ballesteros, R. Sánchez, Cost-effectiveness of conventional cytology and HPV DNA 378 testing for cervical cancer screening in Colombia. Salud Pública México 50, 276–285 379 (2008).
- 380 N. G. Campos, M. Mvundura, J. Jeronimo, F. Holme, E. Vodicka, J. J. Kim, Cost-9. 381 effectiveness of HPV-based cervical cancer screening in the public health system in 382 Nicaragua. BMJ Open 7, e015048 (2017).
- 383 10. S. J. Goldie, L. Gaffikin, J. D. Goldhaber-Fiebert, A. Gordillo-Tobar, C. Levin, C. Mahé, 384 T. C. Wright, Cost-Effectiveness of Cervical-Cancer Screening in Five Developing 385 Countries. N. Engl. J. Med. 353, 2158-2168 (2005).
- 386 11. J.-F. Shi, K. Canfell, J.-B. Lew, F.-H. Zhao, R. Legood, Y. Ning, L. Simonella, L. Ma, Y.-387 J. Kang, Y.-Z. Zhang, M. A. Smith, J.-F. Chen, X.-X. Feng, Y.-L. Qiao, Evaluation of 388 primary HPV-DNA testing in relation to visual inspection methods for cervical cancer 389 screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer 11, 239 (2011). 390

- P. E. Gravitt, P. Paul, H. A. Katki, H. Vendantham, G. Ramakrishna, M. Sudula, B.
   Kalpana, B. M. Ronnett, K. Vijayaraghavan, K. V. Shah, for the C. S. Team,
   Effectiveness of VIA, Pap, and HPV DNA Testing in a Cervical Cancer Screening
   Program in a Peri-Urban Community in Andhra Pradesh, India. *PLOS ONE* 5, e13711
   (2010).
- 396 13. K. P. Msyamboza, T. Phiri, W. Sichali, W. Kwenda, F. Kachale, Cervical cancer
  397 screening uptake and challenges in Malawi from 2011 to 2015: retrospective cohort
  398 study. *BMC Public Health* 16, 806 (2016).
- 399 14. A. Garcia, M. Juarez, N. Sacuj, E. Tzurec, K. Larson, A. Miller, P. Rohloff, Loss to
  400 Follow-Up and the Care Cascade for Cervical Cancer Care in Rural Guatemala: A
  401 Cross-Sectional Study. *JCO Glob. Oncol.* 8, e2100286 (2022).
- 402 15. P. Habinshuti, M. Hagenimana, C. Nguyen, P. H. Park, T. Mpunga, L. N. Shulman, A.
  403 Fehr, G. Rukundo, J. B. Bigirimana, S. Teeple, C. Kigonya, G. F. Ndayisaba, F.
  404 Uwinkindi, T. Randall, A. C. Miller, Factors Associated with Loss to Follow-up among
  405 Cervical Cancer Patients in Rwanda. *Ann. Glob. Health* 86, 117.
- 406 16. A. K. Bhattacharyya, J. D. Nath, H. Deka, Comparative study between pap smear and
  407 visual inspection with acetic acid (via) in screening of CIN and early cervical cancer. J. 408 Life Health 6, 53–58 (2015).
- 409 17. L. Gaffikin, J. A. McGrath, M. Arbyn, P. D. Blumenthal, Visual inspection with acetic
  410 acid as a cervical cancer test: accuracy validated using latent class analysis. *BMC Med.*411 *Res. Methodol.* 7, 36 (2007).
- 412 18. M. J. Huchko, J. Sneden, G. Sawaya, K. Smith-McCune, M. Maloba, N. Abdulrahim, E.
  413 A. Bukusi, C. R. Cohen, Accuracy of Visual Inspection with Acetic Acid to detect
  414 Cervical Cancer Precursors Among HIV-infected Women in Kenya. Int. J. Cancer J. Int.
  415 Cancer 136, 392–398 (2015).
- 416 19. H. J. Prudden, S. L. Achilles, C. Schocken, N. Broutet, K. Canfell, H. Akaba, P. Basu, N. 417 Bhatla, Z. M. Chirenje, S. Delany-Moretlwe, L. Denny, D. G. Gamage, R. Herrero, R. 418 Hutubessy, L. L. Villa, R. Murillo, J. T. Schiller, M. Stanley, M. Temmerman, F. Zhao, G. 419 Ogilvie, D. C. Kaslow, P. Dull, S. L. Gottlieb, Therapeutic HPV Vaccine PPC Expert 420 Consultation Group\*, Understanding the public health value and defining preferred 421 product characteristics for therapeutic human papillomavirus (HPV) vaccines: World 422 Health Organization consultations, October 2021-March 2022. Vaccine 40, 5843–5855 423 (2022).
- 424 20. A. Yang, E. Farmer, T. C. Wu, C.-F. Hung, Perspectives for therapeutic HPV vaccine
  425 development. *J. Biomed. Sci.* 23, 75 (2016).
- 426 21. Janssen Vaccines & Prevention B.V., "A Randomized, Double-blind, Placebo427 controlled, First-in-Human, Phase 1/2a Study to Evaluate Safety, Reactogenicity and
  428 Immunogenicity of Monovalent HPV16 and HPV18 Ad26-vectored Vaccine

- 429 Components and an MVA-vectored HPV16/18 Vaccine Component in Otherwise
- 430 Healthy Women With HPV16 or 18 Infection of the Cervix" (Clinical trial registration
- 431 NCT03610581, clinicaltrials.gov, 2021);
- 432 https://clinicaltrials.gov/ct2/show/NCT03610581.
- 433 22. J. C. Spencer, N. G. Campos, E. A. Burger, S. Sy, J. J. Kim, Potential effectiveness of a 434 therapeutic HPV intervention campaign in Uganda. Int. J. Cancer 150, 847-855 (2022).
- 435 23. R. M. Stuart, J. A. Cohen, C. C. Kerr, R. G. Abeysuriya, M. Zimmermann, D. W. Rao, M. 436 C. Boudreau, D. J. Klein, HPVsim: An agent-based model of HPV transmission and 437 cervical disease. medRxiv [Preprint] (2023).
- 438 https://doi.org/10.1101/2023.02.01.23285356.
- 439 24. C. Porras, S. H. Tsang, R. Herrero, D. Guillén, T. M. Darragh, M. H. Stoler, A. 440 Hildesheim, S. Wagner, J. Boland, D. R. Lowy, J. T. Schiller, M. Schiffman, J. Schussler, 441 M. H. Gail, W. Quint, R. Ocampo, J. Morales, A. C. Rodríguez, S. Hu, J. N. Sampson, 442 A. R. Kreimer, EFFICACY OF THE BIVALENT HPV VACCINE AGAINST HPV-16/18-443 ASSOCIATED PRECANCER: LONG-TERM FOLLOW-UP RESULTS FROM THE COSTA 444 RICA HPV VACCINE TRIAL (CVT). Lancet Oncol. 21, 1643–1652 (2020).
- 445 25. A. Ibrahim Khalil, L. Zhang, R. Muwonge, C. Sauvaget, P. Basu, Efficacy and safety of 446 therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-447 analysis of phase II/III clinical trials. BMJ Open 13, e069616 (2023).
- 448 26. T. Shibata, S. Shah, T. Evans, H. Coleman, B. J. Lieblong, H. J. Spencer, C. M. Quick, 449 T. Sasagawa, O. W. Stephens, E. Peterson, D. Johann, Y.-C. Lu, M. Nakagawa, 450 Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a 451 Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial 452 Lesion Regressed. Front. Immunol. 12, 645299 (2021).
- 453 27. M. Singh, R. P. Jha, N. Shri, K. Bhattacharyya, P. Patel, D. Dhamnetiya, Secular trends 454 in incidence and mortality of cervical cancer in India and its states, 1990-2019: data 455 from the Global Burden of Disease 2019 Study. BMC Cancer 22, 149 (2022).
- 456